Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update.
Kevin McFarthingSue BuffGary RafaloffKenneth PitzerBrian FiskeAnaya NavangulKatelyn BeissertAleksandra PilcickaRosie FuestRichard K WyseSimon R W Stott
Published in: Journal of Parkinson's disease (2024)
The drug development pipeline for PD remains in a robust state with a wide variety of approaches being developed and evaluated in Phase 1 and 2. Yet again, however, only a limited number of DMTs are transitioning to Phase 3.